ArticleBMC infectious diseases2026
Endovascular aneurysm repair combined with local and systemic antibacterial treatment for infected aorto-iliac artery aneurysms caused by Brucella.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrucella-induced aorto-iliac aneurysms (with < 200 documented cases globally) present unique therapeutic challenges due to their dual pathology of structural fragility and persistent bacteremia. Despite their life-threatening nature, no consensus exists on optimal management, particularly for patients unsuitable for open surgical reconstruction. This single-center case series provides critical insights into endovascular salvage strategies for this orphan disease.
methodsA retrospective analysis was conducted on 16 consecutive patients with Brucella-infected aorto-iliac aneurysms undergoing endovascular aneurysm repair (EVAR) with adjunctive local and systemic antimicrobial therapy at our institution between January 2019 and June 2025.
resultsThe cohort demonstrated a 30-day mortality rate of 6.3% (1/16) and all-cause mortality of 31.3% (5/16) during a mean follow-up of 31.1 months. Notably, one patient (6.3%) without local gentamicin-fibrin sealant application developed distal aneurysm recurrence leading to fatal hematemesis at 48 months. In this cohort, Three patients died as a consequence of self-discontinuation of antibiotic therapy: two patients (12.5%) succumbed to infectious shock, while one patient experienced fatal aneurysm recurrence and rupture. Among 15 patients receiving standardized protocol (EVAR with intracavitary gentamicin instillation and prolonged antimicrobial therapy), satisfactory aortic remodeling was achieved with significant aneurysm diameter reduction (39.7 vs. 44.5 mm, P < 0.01). Reintervention rate was 6.3% (1 / 16) for iliac occlusion.
conclusionsAlthough radical open repair with complete debridement should remain the preferred approach for physiologically eligible patients, our findings suggest that EVAR combined with intracavitary antibiotic delivery and rigorously monitored antimicrobial therapy may be a viable alternative in select cases. This hybrid strategy requires meticulous patient selection, sustained infection control, and strict therapeutic compliance to mitigate long-term reinfection risks. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.